Three Things to Look Forward to at #ESMO23

The European Society for Medical Oncology (ESMO) Congress 2023 kicks off on October 20 in Madrid, convening some of the world’s most influential oncology experts to discuss the latest advances in cancer care. Amgen is excited to showcase data that demonstrate the progress we are making across a range of tough to treat cancers, including small cell lung cancer (SCLC), metastatic colorectal cancer (mCRC) and metastatic castration-resistant prostate cancer (mCRPC).

1. An Exciting Potential Target for Patients With SCLC in the Third-Line Setting

SCLC remains one of the most aggressive solid tumor cancers, and currently, there are no therapies specifically approved to treat patients in the third-line setting.^1,2 Key data will be presented during a Proffered Paper Oral Presentation from Amgen’s Phase 2 DeLLphi-301 trial, which evaluated tarlatamab – an investigational bispecific T-cell engager (BiTE^®) molecule that targets the delta-like ligand 3 (DLL3) protein – in patients with SCLC who had failed two or more prior lines of treatment.³

2. Utilizing a Combination Approach to Hopefully Expand KRAS Inhibition in mCRC

Patients with KRAS G12C-mutated metastatic CRC, which is present in approximately 3-5% of cases, face a challenging prognosis and have limited treatment options.^4-6 As part of Amgen’s comprehensive CodeBreaK global development program, new investigational combination treatment data will be presented during a Presidential Symposium Oral Presentation from the CodeBreaK 300 trial in patients with chemorefractory KRAS G12C-mutated metastatic CRC.⁷

3. Amgen’s Robust Pipeline Further Fuels Progress

With a biology-first approach, Amgen is advancing investigational medicines in its pipeline across a range of biomarker-driven pursuits. At ESMO, interim results will be presented from a Phase 1 study evaluating investigational xaluritamig (formerly AMG 509) in mCRPC, which represent the first data readout for this molecule and expands Amgen’s lineup of T-cell engagers.⁸ Additionally, safety results from the FORTITUDE-102 Phase 1b trial of investigational bemarituzumab plus immunotherapy and chemotherapy in advanced gastric/gastroesophageal junction cancers support Amgen’s immuno-oncology combination approach in patients with serious unmet need.⁹ Research will also be presented supporting Amgen’s KRAS^G12C inhibitor in advanced non-small cell lung cancer.^10-13

Additional information of the presentations can be found in our press release here.

To continue to educate around the high unmet needs in mCRC and SCLC, Amgen is launching unique QR codes during the Congress that illustrate Amgen’s commitment to exploring unique targets to drive the advancement of innovative treatment solutions for physicians and their patients. Use your phone to scan the QR codes below to learn more.

Be sure to follow Amgen Oncology on X (formerly known as Twitter) and LinkedIn for real-time updates throughout ESMO.

---

References:

1. American Cancer Society. Cancer Facts and Figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf. Accessed September 14, 2023.
2. Coutinho AD, et al. Lung Cancer. 2019;127:53-58.
3. Paz-Ares L. Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study. Paper presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.
4. Neumann J, et al. Pathol Res Pract. 2009;205(12):858-862.
5. Jones RP, et al. Br J Cancer. 2017;116(7):923-929.
6. Wiesweg M, et al. Oncogene. 2019;38(16):2953-2966.
7. Pietrantonio F. Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 300 phase III study. Paper presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.
8. Kelly W. Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Paper presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.
9. Wainberg ZA. Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1. Poster presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.
10. Audigier-Valette C. Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort. Poster presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.
11. Lena H. Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU). Poster presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.
12. Girard N. Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort. Poster presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.
13. Reguart-Aransay N. Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study). Poster presented at: 2023 European Society for Medical Oncology; October 20-24, 2023; Madrid, Spain.